Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent Score Card: Kyle Bass Gets 17 IPR Reviews Granted, 14 Denied

This article was originally published in The Pink Sheet Daily

Executive Summary

Bass wins review of four Acorda patents based on SEC registration filing; Patent Trial and Appeal Board declines to institute inter partes review of Enbrel patent and Insys' Subsys patents but okays trial on Juxtapid patents.

You may also be interested in...



Acorda Defeats Kyle Bass, Now Awaits Ruling In Ampyra ANDA Litigation

Patent Trial and Appeal Board upheld validity of four Acorda patents; district court judge to issue decision on five patents. Victory would block generic competition until 2025.

PTO Affirms Shire’s Lialda Patent; First Decision In Kyle Bass IPR Case

Patent board has instituted 19 other inter partes review proceedings sought by the hedge fund manager and declined to institute 14.

Patent Process Reforms Proposed By US PTO Could Be ‘Quite Burdensome’ For Applicants

Patent office requests comments on its proposed initiatives, with continuation patents appearing a particular target. PTO asks if filing a terminal disclaimer for patents that are a variation of each other should be an admission they are obvious.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel